Eli Lilly adds ALS drug prospect with QurAlis deal

Eli Lilly adds ALS drug prospect with QurAlis deal

Source: 
BioPharma Dive
snippet: 

Lilly will pay the startup $45 million upfront for an RNA-based therapy in early development, and begin a research collaboration to unearth other, similar medicines.